Synlab has collaborated with genomic and theranostic firm OncoDNA to offer the OncoDeep biomarker test for cancer therapy selection in Germany.

As part of the collaboration, Synlab Laboratories in Germany will have access to the OncoDeep test to perform comprehensive testing of solid tumours and provide support for oncologists.

The test is based on the analysis of more than 600 genes, as well as the measurement of genomic signatures, such as loss of heterozygosity (LOH), tumour mutational burden (TMB), homologous recombination deficiency (HRD) and microsatellite instability (MSI).

It was developed to determine whether a patient is eligible for targeted treatment or immunotherapy.

Synlab noted that immunohistochemistry (IHC) analyses will also be performed to measure protein expression and check patients’ eligibility for anti-cancer drugs.

The company’s laboratories in Mannheim and Jena will run the OncoDEEP test and operate the complete process, from test ordering to clinical recommendation reporting.

Synlab Germany human genetics, pathology and cytology head Dr Christian Mayer said: “OncoDeep is a real asset for oncology diagnostics offering in Germany.

“Particularly in comparison to a single biomarker test, the chance to comprehensively test and predict patient responses to a variety of treatments provides significant benefit to patients and doctors and ultimately delivers accurate decision support on the most effective treatment options.”

The transfer of the OncoDeep test technology to Synlab is ongoing, and processing of the first patient samples is expected early in the second quarter.

OncoDNA CEO Bernard Courtieu said: “Biomarker testing has the potential to improve patient outcomes and health quality. Improving access to these tests should be a priority worldwide. This collaboration will further support the uptake of precision medicine across Germany.”